What's happening with the Medibank share price today?

Medibank made a commitment at the start of the pandemic that it would not profit from COVID-19.

| More on:
excited young female in business attire and wearing glasses is holding up $100 notes in both hands.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medibank Private Ltd (ASX: MPL) share price is slightly in the green in early morning trade on Thursday.

Shares in the S&P/ASX 200 Index (ASX: XJO) healthcare stock closed yesterday trading for $3.50. Shares are currently changing hands for $3.505, up 0.14%.

This comes after Australia's biggest health insurer updated the market on its ongoing COVID-19 support package and give-back program.

What did the ASX 200 health insurer report?

In an announcement unlikely to have a direct material impact on the Medibank share price today, the health insurer announced it would return another $125 million to its customers.

Medibank has now provided $1.15 billion in support to its customers since the start of the global pandemic in early 2020.

The company said its customers would receive funds directly in their bank accounts. The new round of support will be up to $91 for extras-only policies and up to $402 for hospital and extras policies.

Medibank and ahm customers can expect those funds by October.

The cash return is funded from additional COVID-19 permanent net claims savings. Management said it would not impact the insurer's operating earnings for H1 2023. This is why I don't expect the new round of support funds will drag on the Medicare share price.

Commenting on the support package, group executive Milosh Milisavljevic said, "We have now given back $1.15 billion to customers through our COVID-19 give-back program since the start of the pandemic."

Milisavljevic continued:

This year alone we have returned $408 million to customers through cash backs, premium increase deferrals and rolling over extras limits. At a time when people are really feeling the pinch of cost-of-living pressures, we know this extra cash in their pocket will be welcomed.

We made a commitment at the start of the pandemic that we would not profit from COVID-19, and we've stuck by that promise.

Clients holding an active hospital and/or extras policy at any time during the first half of 2023 will be eligible for some portion of the cash-back package.

Medibank share price snapshot

The Medibank share price has been a strong performer in 2023, up 21% year to date.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Healthcare Shares

Guess which ASX small cap stock is jumping on 'significant milestone'

This stock is ending the week in style. Let's see what is giving its shares a boost today.

Read more »

Healthcare Shares

Are CSL and this ASX 200 healthcare stock buys in January?

Is now a good time to pick up these shares? Let's see what analysts are saying.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Communication Shares

2 ASX shares expected to report strong earnings this quarter

Analysts expect a strong set of upcoming numbers for these ASX heavyweights

Read more »

A women has her eyes checked at the optometrist.
Healthcare Shares

Is Medibank stock a good buy?

Can this company provide healthy returns?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on US FDA approval news

This share is giving its shareholders an early Christmas present.

Read more »

A senior pharmacist talks to a customer at the counter in a shop
Healthcare Shares

Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?

Can investors still make healthy returns with this stock?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »